JPY 610.0
(-0.65%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 87.68 Million JPY | 1.33% |
2022 | 86.53 Million JPY | 27.73% |
2021 | 67.74 Million JPY | 5.69% |
2020 | 64.1 Million JPY | -18.86% |
2019 | 79 Million JPY | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | 19.34 Million JPY | -13.47% |
2023 Q2 | 22.46 Million JPY | -3.36% |
2023 Q1 | 23.24 Million JPY | 14.42% |
2023 Q4 | 22.35 Million JPY | 14.0% |
2023 Q3 | 19.61 Million JPY | -12.71% |
2023 FY | 87.68 Million JPY | 1.33% |
2022 Q3 | 21 Million JPY | 7.08% |
2022 FY | 86.53 Million JPY | 27.73% |
2022 Q4 | 20.31 Million JPY | -3.25% |
2022 Q2 | 19.61 Million JPY | 0.0% |
2021 FY | 67.74 Million JPY | 5.69% |
2020 FY | 64.1 Million JPY | -18.86% |
2019 FY | 79 Million JPY | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Kyowa Kirin Co., Ltd. | 320.62 Billion JPY | 99.973% |
Astellas Pharma Inc. | 1212.36 Billion JPY | 99.993% |
Chugai Pharmaceutical Co., Ltd. | 693 Billion JPY | 99.987% |
Ono Pharmaceutical Co., Ltd. | 375.54 Billion JPY | 99.977% |
Santen Pharmaceutical Co., Ltd. | 163.87 Billion JPY | 99.946% |
JCR Pharmaceuticals Co., Ltd. | 31.25 Billion JPY | 99.719% |
Daiichi Sankyo Company, Limited | 1181.79 Billion JPY | 99.993% |
Otsuka Holdings Co., Ltd. | 1407.34 Billion JPY | 99.994% |